Japan to Enact Law Supporting Domestic Vaccine Production... Guarantees for Unprofitable Infectious Disease Treatments
Nikkei: "Ministry of Health, Labour and Welfare Begins Discussions on Proposed Revisions"
The Japanese government has decided to enact legislation to support domestic vaccine production in preparation for future infectious disease outbreaks. The plan aims to ensure that the production capacity developed by companies during the COVID-19 pandemic is preserved, while also guaranteeing a certain level of income for infectious disease treatments that are difficult to profit from due to low demand during normal times.
According to Nikkei on the 21st, the Ministry of Health, Labour and Welfare of Japan has begun these discussions with a view to revising the Infectious Diseases Control Law. After collecting feedback, the ministry reportedly plans to submit a bill reflecting these revisions during next year's regular session of the National Diet.
A person is holding Novavax's COVID-19 vaccine "Nuvaxovid" on the 18th (local time) in Schwenksville, Pennsylvania, USA. Photo by Reuters Yonhap News
View original imageThe Ministry of Health, Labour and Welfare has already requested 76 billion yen (equivalent to 654.6 billion won) in the budget for next year to maintain vaccine production facilities. The government intends to continue supporting companies capable of producing COVID-19 vaccines, especially those that can respond to variant strains. Nikkei reported that, with support from the ministry, five companies including Daiichi Sankyo, Meiji Holdings, and Takeda Pharmaceutical Company have obtained licenses for manufacturing and selling vaccines, having received pharmaceutical approvals.
Nikkei pointed out that the Japanese government's drive to maintain a domestic vaccine production system is based on lessons learned from the COVID-19 experience. At the time, Japan relied on imports from the United States and Europe, which had advanced vaccine development and production capabilities. This dependence, coupled with export restrictions in some regions, led to delays in the domestic vaccination rollout.
For this reason, the Japanese government has continued large-scale fiscal outlays to expand its domestic vaccine production infrastructure. Since 2020, the Ministry of Health, Labour and Welfare launched the “Emergency Improvement Project for Vaccine Production Systems,” which provided support for corporate production facilities and clinical trial expenses. As of the end of March last year, up to approximately 260 billion yen (2.2395 trillion won) had been provided to eight companies. However, as this project is scheduled to end this year, the government now plans to establish a support system through legal revisions that will allow domestic production capacity to be maintained continuously.
Support will also be strengthened not only for vaccines but also for infectious disease treatments that are difficult to secure profitability for due to low patient numbers during normal times. The Japanese government has included 20.6 billion yen (equivalent to 177.4 billion won) in next year's budget request to either directly purchase relevant pharmaceuticals or introduce a program that guarantees a certain level of revenue. Treatments for illnesses such as Ebola hemorrhagic fever and tick-borne severe fever with thrombocytopenia syndrome (SFTS) are being considered as targets for support.
The Japanese government's growth strategy, finalized in July, also set a goal of securing enough vaccines for the roughly 120 million people that make up the entire Japanese population in the event of the next infectious disease crisis. Nikkei added that “the government will also consider establishing a new fund to maintain vaccine production capacity, through future legislative arrangements.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
- I have checked that all company names and proper nouns reflect official names, especially for Daiichi Sankyo, Meiji Holdings, Takeda Pharmaceutical Company, and Nikkei (Nihon Keizai Shimbun).
- All numbers and currency units (yen and won) have been preserved and converted as per the facts in the article.
- HTML tags and special variables
A person is holding Novavax's COVID-19 vaccine "Nuvaxovid" on the 18th (local time) in Schwenksville, Pennsylvania, USA. Photo by Reuters Yonhap News
View original image- The translation faithfully conveys the parallel structure of reasons and causes as stated in the original.
- There are no Korean or non-English terms left in the output.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.